Pipeline Overview

Pipeline Overview

We have a robust drug development pipeline at various clinical and pre-clinical stages with the two most advanced indications expected to file NDAs in China in first half of 2019 for NSCLC and in early 2019 for CIN, and in the U.S. in 2020 for NSCLC and in second half of 2019 for CIN.